This trial is evaluating whether Cytarabine will improve 2 primary outcomes, 6 secondary outcomes, and 1 other outcome in patients with Leukemia. Measurement will happen over the course of From the first day of treatment until any failure (resistant disease, relapse, or death), assessed up to 4 years.
This trial requires 50 total participants across 2 different treatment groups
This trial involves 2 different treatments. Cytarabine is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Approximately 23,000 people get leukemia and AML in the United States each year. People with acute lymphocytic leukemia are at higher risk and are expected to recover more slowly. People with acute myeloid leukemia are at lower risk but have a worse prognosis, and people with chronic myelogenous leukemia have a better prognosis. The prognosis of adults who have been diagnosed with ALL, AML, or CML declines once the cancer has become chronic.
Cure of leukemia could only be achieved when the cancerous genes are completely removed from the leukemia cells at the acute phase of the disease by employing high-dose therapy and intensive supportive care in addition to conventional consolidation therapies. However, the therapeutic efficacy is limited due to high rates of serious late treatment-related toxicities and the low rate of complete and long-term CR.
There are dozens of possible drug targets for leukemias, and almost all of these could potentially be treated using drug therapy. However, several drugs have had their use curtailed due to intolerable side effects or unacceptably limited treatment benefits.
The signs of leukemia are diverse and depend both on what type of leukemia is present and the severity of the disease. Patients with AML experience symptoms that tend to be more severe than patients with ALL or CLL/SLL. All of these signs can be present without any specific underlying medical condition, especially in the setting of minimal residual disease, which often causes fever, night sweats, fatigue, an enlarged liver, and increased liver tests. In addition to the symptoms of fatigue, anemia, or other medical problems, most patients may also experience nausea, abdominal pain, or diarrhea because of malabsorption of key nutrients from the gastrointestinal tract.
Leukemia can have multiple contributing causes, but exposure to certain chemicals or radiation during childhood or pregnancy are more likely. Leukemogenesis depends upon environmental exposures, as well as genetic factors. Leukemogenesis also involves many cell types in the immune system, such as myeloid cells, leukocytes, and lymphocytes. Leukemogenesis is more common in children, with most cases between ages 4 and 12, although it has been reported in neonates. Leukemogenesis is more common in males. leukemogenesis is a rare cancer with a worldwide occurrence.
Cancer development can be due to an assortment of factors including environmental and inherited factors. Leukemogenesis is the process of creating cancer. The most common cause of leukemia is a mutation in the DNA nucleotides. A person's genetic makeups are inherited when they are born. Genetic causes can predispose a person to develop certain forms of cancer at certain ages. Leukemia does not arise from genes. When a single parent who has one child with leukemia does not have a specific chromosomal abnormalities that can cause leukemia, she or he does not have an increased risk of passing on cancer-causing mutations. Genetic causes of cancer only account for 5-10% of cases.
Based on our results combined cyclophosphamide regimen and conventional therapy was superior to a placebo. Cyclophosphamide is a drug recommended as a possible treatment for AML in children. However, further randomized controlled studies are needed in order to confirm these results.
A study in the UK has proven that there is a strong genetic link between myeloid and lymphoid leukaemia in some families. More research will be needed to establish how this genetic link causes the development of the disease.
In North America, leukemia-related deaths typically become apparent in the late winter or early spring (January or February) and gradually decline in autumn (September or October). The trend observed in Europe and China reflects that leukemia is more common in warm, humid climates but can occur at any time of year.
This article describes the common treatment for acute or chronic lymphocytic leukemia when patients are treated with cytostatic agents, specifically cyclophosphamide. I.v. cyclophosphamide should be given.
Leukemia may be caused primarily by environmental exposures; however, genetic mutations are a major cause because all cells in the body have genes that may cause cancer. The cancer is called leukemia because it affects the white blood cells (leukocytes) in the bloodstream. The white blood cells are constantly being born and dying in our blood. The number can also vary a lot. Those cancer cells that don't get caught and killed by immune cells stay in the blood and become dormant. Then when they are in the right place, they can make a person sick.
The research agenda for the treatment of acute leukemia is diverse, focused on research into molecular and targeted therapeutics, and the development and application of novel agents, the development of novel agents based on resistance mechanisms, and new approaches to relapse.